ArticleHead and neck pathology2014
Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.
Article in Head and neck pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review.Epigenetics · 2014Pooled it
- Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer.Head & neck · 2026Article
- Pretreatment Chromosomal Instability Correlates With Radiation Sensitivity in Squamous Cell Cancers.International journal of radiation oncology, biology, physics · 2026Article
- The impact of histopathology on prognosis of squamous cell carcinoma of the larynx: can we do better?Virchows Archiv : an international journal of pathology · 2025Review
- Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.Neoplasia (New York, N.Y.) · 2025Article
- Establishment of a diverse head and neck squamous cancer cell bank using conditional reprogramming culture methods.Journal of medical virology · 2023Article
- High expression of NFX1-123 in HPV positive head and neck squamous cell carcinomas.Head & neck · 2022Article
- Article
- Prognostic role of human papilloma virus status in hypopharyngeal squamous cell carcinoma.Laryngoscope investigative otolaryngology · 2020Article
- HPV in non-oropharyngeal head and neck cancer: does it matter?Annals of translational medicine · 2020Article
- Risk factors for human papillomavirus-positive nonoropharyngeal squamous cell carcinoma.Head & neck · 2020Article
- Association of viral load and physical status of HPV-16 with survival of patients with head and neck cancer.Ecancermedicalscience · 2020Article
- Density of CD3+ and CD8+ cells in gingivo-buccal oral squamous cell carcinoma is associated with lymph node metastases and survival.PloS one · 2020Article
- Review
- Association between pretreatment obesity, sarcopenia, and survival in patients with head and neck cancer.Head & neck · 2019Article
- Brain-Derived Neurotrophin and TrkB in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2019Article
- Detection of HPV infection in head and neck cancers: Promise and pitfalls in the last ten years: A meta-analysis.Molecular and clinical oncology · 2019Article
- Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival.Cancers of the head & neck · 2019Article
- Nerve Growth Factor (NGF)-Receptor Survival Axis in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2018Article
- Apparent Diffusion Coefficient Histograms of Human Papillomavirus-Positive and Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma: Assessment of Tumor Heterogeneity and Comparison with Histopathology.AJNR. American journal of neuroradiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Recent evidence suggests that human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) patients have better survival than HPV-negative patients. However, it is unclear if similar patterns for survival exist across different tumor sites, and whether HPV-associated prognosis is modified by type of treatment. We prospectively tested 222 histologically confirmed HNSCC primary tumors for HPV DNA by PCR and HPV E6/E7 RNA by RT-PCR prior to treatment at a large urban health center. Cox proportional hazard ratio models were constructed to assess HPV-associated differences in overall and disease-specific survival adjusting for clinical and demographic covariates. HPV detection varied significantly by primary HNSCC tumor site, from 35 % for oropharynx, to 25 % for hypopharynx, 5 % for larynx, and 3 % for oral cavity (p < 0.0001), with HPV16 accounting for the majority (95 %) of HPV-positive tumors. The hazard-risk of overall and disease-specific death comparing HPV16-positive versus negative oropharyngeal HNSCC was reduced by 74 and 89 %, respectively (p values < 0.05), and was independent of other prognostic indicators; no statistically significant changes in outcomes were observed for non-oropharyngeal HNSCC sites. Prediction of overall survival was better with combined DNA and RNA HPV16 positive PCR detection. There was no difference in HPV16-associated survival whether patients received either surgery or (chemo)radiotherapy as their initial treatment modality. Improved HPV-associated HNSCC survival is limited to patients with oropharyngeal primaries. No selective treatment advantage is observed for HPV-positive tumors, although clinical trials are needed to evaluate which treatment modalities provide the most benefit for HPV-positive HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.